I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Osteoporosis is a widely prevalent public health problem with substantial morbidity and mortality. Poor nutrition, inadequate exposure to sunlight and low vitamin D status contribute to severe osteoporosis in India.[@ref1][@ref2]

In adults, severe vitamin D deficiency can cause osteomalacia, which is characterized by inadequate mineralization of the newly formed osteoid. Vitamin D deficiency is believed to cause secondary hyperparathyroidism, leading to an increase in the bone turnover and bone loss.[@ref3][@ref4] A negative correlation between serum intact parathyroid hormone (iPTH) (the whole PTH molecule consisting of the N-terminal PTH; midmolecule PTH and C-terminal PTH) and serum 25-hydroxyvitamin D (25(OH) D) has been noted in both Caucasian and non Caucasian populations.[@ref3][@ref5][@ref6][@ref7][@ref8] However, from several studies it is has become evident that not all patients with hypovitaminosis D develop secondary hyperparathyroidism.[@ref9][@ref10] It is hypothesized that low 25(OH) D concentrations by virtue of development of secondary hyperparathyroidism could be a contributing factor to the low BMD.

Current standard approach for diagnosing osteoporosis is the estimation of bone mineral density (BMD) using dual energy X-ray absorptiometry (DEXA). Low serum 25(OH) D concentrations have been reported in community-dwelling southeast Asian and far east Asian women with no previous history of osteoporosis. Varying effects of 25(OH) D concentrations on bone mineral density (BMD) were reported in these studies.[@ref5][@ref6][@ref7][@ref11] However, very few studies have investigated the status of vitamin D in adults with prevalent low BMD and different rates of vitamin D insufficiency have been reported in these investigations.[@ref12][@ref13][@ref14][@ref15] Another such study on southeast Asians included very few Indian subjects (3.1% of total study subjects).[@ref16]

The objectives of this study were (1) to estimate the distribution of serum 25(OH) D levels and (2) to assess the correlation among 25(OH) D levels, iPTH levels and BMD in a population of Indian patients presenting for the evaluation of low BMD.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

All patients presenting with symptoms or risk factors of osteoporosis were subjected to DEXA scanning for evaluation of osteopenia or osteoporosis. The study population included patients seen primarily at our OPD and patients referred by the department of orthopedics and general medicine. The study was duly approved by the institutional ethics committee. Patients were included into the study after obtaining an informed consent. A social and medical history, features of osteoporosis including fragility fracture, intake of medications and supplements, personal history and family history of fractures, loss of height, bone pains and other complaints were elicited. Other important assessments included dietary intake of calcium and exposure to sunlight per day. BMI was calculated as weight in kilograms divided by square of height in meters. The standard deviation (SD) was expressed as T-score. It was calculated as a difference between the measured bone mineral density (BMD) of the patients and the expected bone density value in a normal young person (YN) divided by the population standard deviation (SD).[@ref17] Osteopenia was defined with T-score between −1 and −2.5 and osteoporosis was defined with T-score less than −2.5.[@ref17]
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Patient selection {#sec2-1}
-----------------

### Inclusion criteria {#sec3-1}

All patients who had a low BMD defined as a T-score (determined by DEXA) of \< −1.0 SD at the hip or lumbar spine. (Patients with or without fragility fractures were included).

### Exclusion criteria {#sec3-2}

\(1\) Diagnosis of primary hyperparathyroidism by elevated serum calcium with unsuppressed iPTH levels. (2) Patients with conditions associated with malabsorption of vitamin D, such as inflammatory bowel disease, chronic pancreatitis, or a history of gastric or small bowel resections. (3) Those patients taking any medication (s) that could adversely affect bone metabolism and thus contribute to a decreased BMD by causing vitamin D deficiency like (rifampicin, ketoconazole, phenytoin, valproic acid, corticosteroid, orlistat) etc. (4) Patients with a creatinine clearance ≤50 ml/min. Below this level, there is impaired hydroxylation of 25(OH) D to 1,25-dihydroxyvitamin D.[@ref18] (5) Patients with secondary osteoporosis, prolonged glucocorticoid intake (defined as use of prednisolone in a dosage of more than 5 mg/d for at least 3 months), or significant hepatic or thyroid dysfunction as measured from liver function tests and thyroid profile.

All participants in the study were nonsmokers, denied alcohol consumption, were ambulatory and were not receiving antiosteoporosis agents like (bisphosphonates, calcitonin, hormone replacement therapy, selective estrogen receptor modulators, strontium, or teriparatide).

Biochemical measurements {#sec2-2}
------------------------

Laboratory tests included serum creatinine, albumin, total calcium, inorganic phosphate, liver enzymes, iPTH and 25(OH) D. Serum calcium and serum phosphorus were determined by spectrophotometric analysis; albumin-corrected calcium was calculated by using the following formula: Corrected calcium (in mg/dL) = measured total calcium (in mg/dL) + 0.8 \[4.0- serum albumin (in g/dL)\] (4.0 represents the average serum albumin level (in g/dL). Serum 25(OH) D was measured by radioimmunoassay (DiaSorin Inc., Stillwater, Minnesota) after extraction with acetonitrile. Serum iPTH was measured by chemiluminiscence method on the Beckman Coulter, Unicel Dxl 800 Immunoassay System (Beckman Coulter Inc., Brea, California) using a 2-site sandwich immunoenzymatic chemiluminescent assay. The assay uses a monoclonal anti-PTH antibody conjugated to alkaline phosphatase and paramagnetic particles coated with a goat polyclonal anti-PTH antibody.

Bone mineral density {#sec2-3}
--------------------

The T-score, bone mineral content and BMD were determined at two anatomic sites -- namely the hip and the lumbar spine, using the DEXA (Lunar Corp., Madison, Wisconsin; CV 0.64%). Values of the BMD at the lumbar spine were expressed as the mean of those at the L1 through L4 vertebrae. The T-scores and Z-scores were calculated on the basis of normal reference values for age- and sex-matched subjects (provided by the DEXA manufacturer). The estimation of BMD was done with use of the same machine for all patients participating in the study. Osteopenia was defined T-score \< −1 and osteoporosis as T-score ≤ −2.5.

Statistics {#sec2-4}
----------

The summary data are expressed as mean values ± SD and comparisons between the groups were done using multivariate regression analysis method. Demographics and other characteristics were summarized using descriptive statistics. The independent *t*-test was used to assess the difference in serum 25(OH) D concentrations between patients with and those without fragility fractures. For investigation of the factors affecting iPTH and BMD, multivariate analysis with the linear mixed model was used. The analysis on iPTH levels was performed separately on two groupings of 25(OH) D levels of \<30 ng/ml and ≥30 ng/ml. The factors evaluated for their effect on iPTH were age, sex, race, total calcium intake, duration of calcium intake and continuous values of 25(OH) D level \<30 ng/ml or ≥30 ng/ml. For BMD at the femoral neck, hip and lumbar spine; age, sex, race, body mass index (BMI), continuous values of 25(OH) D level as well as groupings of 25(OH) D levels \<30 ng/ml or ≥30 ng/ml, iPTH level, total calcium intake and groupings of exposure to sunlight (\<15 min daily or ≥15 min daily) were assessed. *P* values were reported for all statistical tests and values \<0.05 were considered significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 102 consecutive patients were selected taking into account the inclusion and exclusion criteria. Baseline demographic characteristics are mentioned in [Table 1](#T1){ref-type="table"}. The multiple regression model \[[Table 2](#T2){ref-type="table"}\] showed that there was no statistically significant associations between serum 25(OH) D concentrations and BMD at the hip (*P* = 0.473) and lumbar spine (*P* = 0.353) after adjustments were made for age, sex, race, BMI, iPTH level, total calcium intake and groupings of exposure to sunlight (\<15 min daily or ≥15 min daily). At the hip; iPTH levels, male gender, BMI and age were found to be significant predictors of BMD. Similarly at the lumbar spine; iPTH levels, BMI, age and male gender were independently predictive of BMD. There was no statistically significant difference in mean serum 25(OH) D levels between patients with and those without fragility fractures (*P* = 0.495), nor were prevalent 25(OH) D levels predictive of fragility fractures after adjustments were made for age, sex, race, BMI, total calcium intake and iPTH levels (*P* = 0.461).

###### 

Baseline demography and biochemical data
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###### 

Multiple regression analysis of the impact of different variables on bone mineral density at lumbar spine and hip
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Forty-four (M:F = 20:24) patients had osteopenia and the rest of the 58 patients (M:F = 18: 40) had osteoporosis. [Table 3](#T3){ref-type="table"} depicts the characteristics of the patients stratified as per T-score. Relationship between 25(OH) D and iPTH level is shown in [Table 4](#T4){ref-type="table"}. For serum 25(OH) D concentrations \<30 ng/ml, we found that for every increase in serum 25(OH) D of 1 ng/ml, there was a 1.03 pg/ml (95% CI, 0.089 to 1.1902; *P* = 0.041) decrease in serum iPTH level after adjustments were made for gender, race, age, total calcium intake and duration of calcium intake. This relationship was not observed at 25(OH) D levels ≥30 ng/ml.

###### 

Clinical and biochemical characteristics of study patients stratified as per their T score
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###### 

Relationship between serum intact parathyroid hormone and 25-hydroxyvitamin D levels
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D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

We investigated the association amongst prevalent 25(OH) D levels, BMD and iPTH levels in patients with osteopenia and osteoporosis. Several studies have documented hypovitaminosis D in people living in countries with abundant sunshine.[@ref2][@ref5][@ref12][@ref19][@ref20] Reasons attributed for the same are, indoor activities with inadequate sun exposure, improper duration and timing of sun exposure, poor dietary intake and genetic factors. Prevalence of vitamin D deficiency in India is alarmingly high.[@ref2][@ref21] Vitamin D deficiency is considered to be present when serum 25(OH) D levels are \<20 ng/ml.[@ref22] Harinarayan *et al*.,[@ref23] have studied 25(OH) D and BMD in women of reproductive (WR) age group and postmenopausal women (PMW) in south India. They have reported vitamin D deficiency in 76% in WR, 70% in PMW and insufficiency in 16.5% in WR and 23% in PMW. Osteoporosis was seen at hip, 15 and 28%; forearm, nil and 11%; lumbar spine antero-posterior (LSAP), 6 and 22%; and LS lateral, 0 and 23% among WR and PMW; respectively. BMD did not correlate with any of the biochemical indices but correlated with BMD at other sites.[@ref23] Marwaha *et al*.,[@ref24] have reported vitamin D deficiency in healthy Indians above the age of 50 years from north India. Vitamin D deficiency was present in 91.2% and insufficiency in 6.8% cases. However, there was no correlation of BMD with 25(OH) D in this study.[@ref24] Previous studies have shown that 25(OH) D concentrations of 30-32 ng/ml are associated with maximal suppression of iPTH.[@ref25][@ref26] Hypovitaminosis D is gaining importance over the fact that it is shown to be associated with many chronic infectious and noninfectious illnesses.[@ref27][@ref28] In our study, prevalence of hypovitaminosis D was 84.3%.

Existing data point to lower average areal BMD values in Asian populations,[@ref17][@ref19][@ref27][@ref28][@ref29] The rates of osteoporotic fractures, in urbanized nations in Asia, approach the rates observed in Caucasian populations.[@ref30] The age-adjusted rates for men and women (per 100,000) are as follows: Hong Kong, 180 and 459; Singapore, 164 and 442; Malaysia, 88 and 218; Thailand, 114 and 289 this is in contrast with US White rates of 187 in men and 535 in women.[@ref30] Vitamin D deficiency is an important risk factor for the development of osteoporosis.[@ref25][@ref26] Some studies have reported a positive correlation between 25(OH) D levels and measured BMD at all sites.[@ref31] Others have found a correlation at the femoral neck but not at other sites.[@ref3][@ref7][@ref32][@ref33] Although some studies have not found any direct correlation between the two at any of the sites.[@ref6][@ref12][@ref34] All these studies were performed in subjects without a known diagnosis of bone loss. When patients with osteoporosis were included, a positive correlation between 25(OH) D levels and BMD at the femoral neck (but not at the lumbar spine) was found in one study;[@ref35] An association between serum 25(OH) D and BMD at the trochanter only was found in one study[@ref13] In a similar study from southeast Asia including patients with low BMD revealed no association between 25(OH) D levels and BMD at the femoral neck, hip, or lumbar spine.[@ref16] Though, we did not measure femoral neck BMD, we too observed lack of association between 25(OH) D levels and BMD at the hip or lumbar spine, however the reason for this lack of association remains unexplained.

In our study population, serum 25(OH) D levels were not directly correlated with BMD. The relationship between serum 25(OH) D concentrations and BMD has been shown to differ between black and white races in population-based studies.[@ref6][@ref12][@ref34][@ref35][@ref36][@ref37] Although African Americans have lower vitamin D levels than do white Americans, they have a lower prevalence of osteoporosis.[@ref38] We did not find an association between prevalent serum 25(OH) D levels and BMD at any anatomic site measured in our patients. Presence of very few cases with extremely low levels of 25(OH) D \<10 ng/ml, could account for the observed association.

Bone density tends to decline in older people because of age-related bone loss. The exact age of attainment of peak bone density at various skeletal sites remains controversial, as does the age at which age-related bone loss begins at each site. In comparison with women, men have a greater bone cross-sectional area and hence a higher BMD.[@ref39][@ref40] We demonstrated BMI, age, male gender and PTH as significant predictors of BMD at hip and lumbar spine. Observations by the study from Singapore were similar with the exception that male gender was not a significant predictor of BMD at the lumbar spine. BMD is shown to be positively correlated with BMI,[@ref41] and the high BMD of overweight individuals has been attributed to several causes, including the permissive effect of weight on the skeleton[@ref42] and vitamin D deficiency causing secondary hyperparathyroidism.[@ref43] BMI in our group of patients with osteopenia was significantly higher than patients with osteoporosis. Our data supports the widely known fact about the protective effect of obesity in preventing osteoporosis. In postmenopausal women, increased body weight has various effects on mature bone and extra skeletal collagen-containing tissues, resulting in increased bone mineral content.[@ref44] Recently, however, an interesting study by Zhao *et al*.,[@ref45] showed that an increased fat mass may not have a beneficial effect on bone if controlled for the mechanical loading effects.

Several studies have shown suppression of iPTH at serum 25(OH) D levels at or around 30 ng/ml,[@ref3][@ref8][@ref9][@ref22][@ref46] with an inverse relationship between iPTH and 25(OH) D at serum 25(OH) D concentrations below 30 ng/ml. Secondary hyperparathyroidism has been proposed as the principal mechanism whereby vitamin D deficiency could contribute to bone loss. The increased serum iPTH level causes an increase in bone turnover, which is associated with primarily cortical but also trabecular bone loss.[@ref47][@ref48] As previously noted, not all patients with hypovitaminosis D develop secondary hyperparathyroidism. Patients with hypovitaminosis D and a blunted PTH response have shown a lower serum calcium concentration, a reduction in bone turnover and protection of bone density in comparison with those who have hypovitaminosis D and secondary hyperparathyroidism.[@ref10] Nevertheless our study observed that levels of 25(OH) D \<30 ng/ml were predictive of iPTH levels and increasing PTH levels were associated with lower BMD at the hip and lumbar spine. This leads to the suggestion that secondary hyperparathyroidism is a potential mediator of bone loss in hypovitaminosis D.

Limitations of our study are a small sample size leading to inadequate power (0.62, normal ≥0.8), single center experience with study population not reflective of the Indian population at large and lack of randomization in the recruitment of patients as most of our subjects were hospital based. The calcium intake and exposure to sunlight were calculated according to the participants' own assertion. However, we still feel that our single center experience would pave way for a longitudinal multicenter study involving larger number of patients to confirm or negate our observations.

To conclude though a direct relationship did not appear to exist between serum 25(OH) D levels and BMD, the significant associations observed between iPTH levels and BMD at the hip and lumbar spine emphasize the critical role of this hormone in bone metabolism and bone health. Advancing age, male gender and BMI are other significant predictors for BMD both at the hip and lumbar spine.
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